Knight Therapeutics (OTCMKTS:KHTRF) Shares Climb 3% – Time to Buy?

Knight Therapeutics Inc. (OTCMKTS:KHTRF)’s share price shot up 3% on Monday. The company traded as high as $7.94 and last traded at $7.94. Approximately 1,400 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 7,320 shares. The stock had previously closed at $7.71.

Wall Street Analyst Weigh In

Separately, Royal Bank Of Canada reiterated an “outperform” rating on shares of Knight Therapeutics in a report on Friday, August 7th. One equities research analyst has rated the stock with a Buy rating. According to data from MarketBeat.com, the company currently has an average rating of “Buy”.

Knight Therapeutics Price Performance

The firm has a 50-day simple moving average of $7.18 and a 200 day simple moving average of $6.61.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a Canadian specialty pharmaceutical company focused on acquiring, licensing, commercializing and, in some cases, developing innovative prescription medicines. The company targets areas of significant unmet medical need, including oncology, rare diseases, neurology, infectious diseases and other specialty-care markets.

Knight works with pharmaceutical and biotechnology partners to bring approved or late-stage therapies to patients. Its activities generally include regulatory support, market access, commercialization and distribution rather than large-scale discovery research.